- ScreenPro’s (SCRN) Covid PCR testing has revealed a significant spike in positivity rates in test results within the film and production industry
- The positivity rate is significantly higher today than at the same time last year
- The COVID-19 crisis remains a burden with considerably more risk to Canadians with new submerged COVID-19 variants
- ScreenPro is a medical technology company
- ScreenPro (SCRN) opened trading at C$0.03
ScreenPro’s (SCRN) Covid PCR testing has revealed a significant spike in positivity rates in testing results within the film and production industry.
According to the company’s PCR testing data, the positivity rate is significantly higher today than at the same time last year.
The current COVID-19 crisis remains a burden with even more risk to Canadians with new submerged COVID-19 variants. Variants of concern include mutations that seem to make the virus more infectious, allowing it to spread more quickly. Variants may also affect the severity of the disease, making it more lethal.
There’s evidence that some variants may negatively impact the effectiveness of certain drugs and vaccines to protect against the virus.
“With the number of people testing positive in our testing data compared to last year and the current spike in Covid cases due to new variants, the Company foresees Covid to be a remaining issue for Canadians. We are happy to help our clients to have a safe work environment,” said Andrew Ryu, Chief Executive Officer and Chairman of the Company.
ScreenPro is a medical technology company that provides turnkey screening solutions with its proprietary medical alerting software. ScreenPro also recently introduced Naturevan Nutrition Ltd. to its portfolio, providing vitamins and supplements that are made in Canada and distributed for sale online.
ScreenPro (SCRN) opened trading at C$0.03.
